Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
…
20,900€
-0,48%
Echtzeit-Aktienkurs Agios Pharmaceuticals
Bid:
Ask:
Nachrichten zur Agios Pharmaceuticals Aktie
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia By Investing.com
Agios Pharmaceuticals stock soars after FDA approves AQVESME for thalassemia…
AGIOs Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new…
Ionis Pharmaceuticals Aktienanalyse: Milliardenmarkt im Blick - RBC Capital erkennt den nächsten Wachstumsschub
Bad Marienberg (www.aktiencheck.de)???????? Ionis Pharmaceuticals hebt ab: RBC Capital sieht neues Kursziel 95 USD und enormes MarktpotenzialIonis Pharmaceuticals Inc. (ISIN:…
Ionis Pharmaceuticals Aktie: Positive Phase-3-Daten beflügeln Analystenmeinung - Upgrade!
New York (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Goldman Sachs:Salveen Richter von Goldman Sachs stuft die Aktie von Ionis Pharmaceuticals Inc.…
Ionis Pharmaceuticals Aktie: Phase-3-Erfolg bei Alexander-Krankheit beflügelt Kursziel
London (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse von Barclays:Die Analystin Gena Wang von Barclays bestätigt für die Aktie von Ionis Pharmaceuticals Inc.…
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
…
Agios Pharmaceuticals: A More Compelling Valuation
…
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
…
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do…
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
…
Agios Pharmaceuticals: A Long Overdue Follow Up
…
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
…
Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this…
Agios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript
…